B7-H3 and ICAM-1 are potentially therapeutic targets for thyroid carcinoma.
B7-H3
ICAM-1
Thyroid cancer
Journal
Diagnostic pathology
ISSN: 1746-1596
Titre abrégé: Diagn Pathol
Pays: England
ID NLM: 101251558
Informations de publication
Date de publication:
10 Jun 2024
10 Jun 2024
Historique:
received:
06
01
2024
accepted:
31
05
2024
medline:
11
6
2024
pubmed:
11
6
2024
entrez:
10
6
2024
Statut:
epublish
Résumé
Although most differentiated thyroid carcinoma has a clinically favorable prognosis, some of specific types of thyroid cancer (such as anaplastic thyroid carcinoma and advanced papillary thyroid carcinoma) show fatal outcomes and require novel treatments. Immunotherapy is a promising avenue for the treatment of advanced thyroid carcinoma. B7-H3 (B7 homolog 3 protein) and ICAM-1 (intercellular adhesion molecule 1), as two important immune checkpoints (ICPs), is becoming hopeful target spots for immunotherapy. A growing amount of evidence has suggested that B7-H3 and ICAM-1 are upregulated in papillary thyroid carcinoma. However, their expression level in specific types of thyroid cancer remains largely unclear. In the present study, we explored the expression level of B7-H3 and ICAM-1 in different types of thyroid carcinoma. In the groups of the TCGA cohort, both B7-H3 and ICAM-1 mRNA were highly expressed in thyroid carcinoma. Furthermore, the patients with Stage2, 61-80y, Follicular thyroid papillary carcinoma and N0 had lower B7-H3 and ICAM-1 mRNA expression. In the groups of our cohort, PTCs and ATCs showed frequently moderate to strong expression of B7-H3 and ICAM-1 protein expression. The significant relevance of B7-H3 staining score with ICAM-1 staining score was observed in TCGA database and our cohort, which might open avenues for the combination therapy in advanced thyroid cancer.
Identifiants
pubmed: 38858715
doi: 10.1186/s13000-024-01504-2
pii: 10.1186/s13000-024-01504-2
doi:
Substances chimiques
Intercellular Adhesion Molecule-1
126547-89-5
B7 Antigens
0
CD276 protein, human
0
ICAM1 protein, human
0
Biomarkers, Tumor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
77Informations de copyright
© 2024. The Author(s).
Références
Cabanillas ME, McFadden DG, Durante C. Thyroid cancer. Lancet. 2016;388(10061):2783–95.
doi: 10.1016/S0140-6736(16)30172-6
pubmed: 27240885
Chen DW, Lang BHH, McLeod DSA, Newbold K, Haymart MR. Thyroid cancer. Lancet. 2023;401(10387):1531–44.
doi: 10.1016/S0140-6736(23)00020-X
pubmed: 37023783
Abdullah MI, Junit SM, Ng KL, Jayapalan JJ, Karikalan B, Hashim OH. Papillary thyroid cancer: genetic alterations and molecular biomarker investigations. Int J Med Sci. 2019;16(3):450–60.
doi: 10.7150/ijms.29935
pubmed: 30911279
pmcid: 6428975
Kim M, Kim BH. Current guidelines for management of medullary thyroid carcinoma. Endocrinol Metab (Seoul). 2021;36(3):514–24.
doi: 10.3803/EnM.2021.1082
pubmed: 34154310
Haugen BR, Alexander EK, Bible KC, et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1–133.
doi: 10.1089/thy.2015.0020
pubmed: 26462967
pmcid: 4739132
Boucai L, Zafereo M, Cabanillas ME. Thyroid cancer: a review. JAMA. 2024;331(5):425–35.
doi: 10.1001/jama.2023.26348
pubmed: 38319329
Bremnes RM, Busund LT, Kilvaer TL, et al. The role of tumor-infiltrating lymphocytes in development, progression, and prognosis of non-small cell lung cancer. J Thorac Oncol. 2016;11(6):789–800.
doi: 10.1016/j.jtho.2016.01.015
pubmed: 26845192
Farkona S, Diamandis EP, Blasutig IM. Cancer immunotherapy: the beginning of the end of cancer? BMC Med. 2016;14:73.
doi: 10.1186/s12916-016-0623-5
pubmed: 27151159
pmcid: 4858828
Mehnert JM, Varga A, Brose MS, et al. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer. BMC Cancer. 2019;19(1):196.
doi: 10.1186/s12885-019-5380-3
pubmed: 30832606
pmcid: 6399859
Capdevila J, Wirth LJ, Ernst T, et al. PD-1 blockade in anaplastic thyroid carcinoma. J Clin Oncol. 2020;38(23):2620–7.
doi: 10.1200/JCO.19.02727
pubmed: 32364844
pmcid: 7476256
Chandrashekar DS, Karthikeyan SK, Korla PK, et al. UALCAN: An update to the integrated cancer data analysis platform. Neoplasia. 2022;25:18–27.
doi: 10.1016/j.neo.2022.01.001
pubmed: 35078134
pmcid: 8788199
Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455–65.
doi: 10.1056/NEJMoa1200694
pubmed: 22658128
pmcid: 3563263
Rizvi NA, Mazieres J, Planchard D, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol. 2015;16(3):257–65.
doi: 10.1016/S1470-2045(15)70054-9
pubmed: 25704439
pmcid: 5726228
Luo Y, Yang YC, Shen CK, et al. Immune checkpoint protein expression defines the prognosis of advanced thyroid carcinoma. Front Endocrinol (Lausanne). 2022;13:859013.
doi: 10.3389/fendo.2022.859013
pubmed: 35574031
Li H, Zhou X, Wang G, et al. CAR-T cells targeting TSHR demonstrate safety and potent preclinical activity against differentiated thyroid cancer. J Clin Endocrinol Metab. 2022;107(4):1110–26.
doi: 10.1210/clinem/dgab819
pubmed: 34751400
Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–64.
doi: 10.1038/nrc3239
pubmed: 22437870
pmcid: 4856023
Hofmeyer KA, Ray A, Zang X. The contrasting role of B7–H3. Proc Natl Acad Sci U S A. 2008;105(30):10277–8.
doi: 10.1073/pnas.0805458105
pubmed: 18650376
pmcid: 2492485
Chapoval AI, Ni J, Lau JS, et al. B7–H3: a costimulatory molecule for T cell activation and IFN-gamma production. Nat Immunol. 2001;2(3):269–74.
doi: 10.1038/85339
pubmed: 11224528
Lupu CM, Eisenbach C, Lupu AD, et al. Adenoviral B7–H3 therapy induces tumor specific immune responses and reduces secondary metastasis in a murine model of colon cancer. Oncol Rep. 2007;18(3):745–8.
pubmed: 17671729
Zhao B, Li H, Xia Y, et al. Immune checkpoint of B7–H3 in cancer: from immunology to clinical immunotherapy. J Hematol Oncol. 2022;15(1):153.
doi: 10.1186/s13045-022-01364-7
pubmed: 36284349
pmcid: 9597993
Zhao B, Huang Z, Zhu X, et al. Clinical significance of the expression of co-stimulatory molecule B7–H3 in papillary thyroid carcinoma. Front Cell Dev Biol. 2022;10:819236.
doi: 10.3389/fcell.2022.819236
pubmed: 35493085
pmcid: 9039293
Yang S, Wei W, Zhao Q. B7–H3, a checkpoint molecule, as a target for cancer immunotherapy. Int J Biol Sci. 2020;16(11):1767–73.
doi: 10.7150/ijbs.41105
pubmed: 32398947
pmcid: 7211166
Hu G, Vogel SM, Schwartz DE, Malik AB, Minshall RD. Intercellular adhesion molecule-1-dependent neutrophil adhesion to endothelial cells induces caveolae-mediated pulmonary vascular hyperpermeability. Circ Res. 2008;102(12):e120–31.
doi: 10.1161/CIRCRESAHA.107.167486
pubmed: 18511851
pmcid: 2664169
Dustin ML, Rothlein R, Bhan AK, Dinarello CA, Springer TA. Induction by IL 1 and interferon-gamma: tissue distribution, biochemistry, and function of a natural adherence molecule (ICAM-1). J Immunol. 1986;137(1):245–54.
doi: 10.4049/jimmunol.137.1.245
pubmed: 3086451
Roland CL, Harken AH, Sarr MG, Barnett CC Jr. ICAM-1 expression determines malignant potential of cancer. Surgery. 2007;141(6):705–7.
doi: 10.1016/j.surg.2007.01.016
pubmed: 17560245
Kotteas EA, Boulas P, Gkiozos I, Tsagkouli S, Tsoukalas G, Syrigos KN. The intercellular cell adhesion molecule-1 (icam-1) in lung cancer: implications for disease progression and prognosis. Anticancer Res. 2014;34(9):4665–72.
pubmed: 25202042
Buitrago D, Keutgen XM, Crowley M, et al. Intercellular adhesion molecule-1 (ICAM-1) is upregulated in aggressive papillary thyroid carcinoma. Ann Surg Oncol. 2012;19(3):973–80.
doi: 10.1245/s10434-011-2029-0
pubmed: 21879273
Zhang KE, Ge SJ, Lin XY, et al. Intercellular adhesion molecule 1 is a sensitive and diagnostically useful immunohistochemical marker of papillary thyroid cancer (PTC) and of PTC-like nuclear alterations in Hashimoto’s thyroiditis. Oncol Lett. 2016;11(3):1722–30.
doi: 10.3892/ol.2016.4104
pubmed: 26998068
pmcid: 4774517
Vedvyas Y, McCloskey JE, Yang Y, et al. Manufacturing and preclinical validation of CAR T cells targeting ICAM-1 for advanced thyroid cancer therapy. Sci Rep. 2019;9(1):10634.
doi: 10.1038/s41598-019-46938-7
pubmed: 31337787
pmcid: 6650612
Gray KD, McCloskey JE, Vedvyas Y, et al. PD1 blockade enhances ICAM1-directed CAR T therapeutic efficacy in advanced thyroid cancer. Clin Cancer Res. 2020;26(22):6003–16.
doi: 10.1158/1078-0432.CCR-20-1523
pubmed: 32887724
pmcid: 7709864